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Abstract
Background: The aetiology of painful diabetic neuropathy is unclear. We have evalu-
ated vitamin D levels in diabetic patients with and without painful neuropathy.
Methods: Forty-three patients with type 1 diabetes and painless (DPN) (n = 20) or
painful (PDN) (n = 23) neuropathy and 14 non-diabetic healthy control subjects (C)
underwent assessment of neurologic deficits, quantitative sensory testing (QST),
electrophysiology, skin biopsy, corneal confocal microscopy (CCM) and measurement
of serum 25(OH)D.
Results: There were no significant differences for age, BMI, HbA1c, lipids, neurologi-
cal deficits, QST, electrophysiology, intra-epidermal nerve fibre density (IENFD) and
corneal nerve morphology between patients with DPN and PDN. Both positive
(hyperalgesia and allodynia) and negative symptoms (paraesthesia and numbness) of
diabetic neuropathy were greater in PDN compared with DPN (P = .009 and P = .02,
respectively). Serum 25(OH)D levels were significantly lower in PDN
(24.0 ± 14.1 ng/mL) compared with DPN (34.6 ± 15.0 ng/mL, P = .01) and controls
(34.1 ± 8.6 ng/mL, P = .03). The odds ratio in favour of painful diabetic neuropathy
was 9.8 [P = .003 (95% CI, 2.2–76.4)] for vitamin D deficiency (<20 ng/mL) and 4.4
[P = .03 (95% CI, 1.1-19.8)] for vitamin D insufficiency (<30 ng/mL).
Conclusions: This study suggests that vitamin D deficiency and insufficiency are
associated with painful diabetic neuropathy.
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1 | BACKGROUND
The prevalence of painful diabetic neuropathy is 21% and painful
symptoms are more prevalent in patients with type 2 diabetes,
females and South Asians.1-4 Painful diabetic neuropathy is character-
ized by symmetrical lower limb paraesthesiae, dysaesthesiae, lancinat-
ing pains and allodynia with nocturnal exacerbation5 and is associated
with significant sleep disturbance and reduced quality of life.6
Observational studies in people with diabetes demonstrate a signifi-
cant association between vitamin D deficiency with paraesthesiae and
numbness,7 the severity of DPN using the neuropathy symptom score,
neurological deficits and electrophysiology,8 impaired nerve conduction
velocity9 and reduced parasympathetic function.10 In a recent study
there was an inverse U-shaped association between serum vitamin D
levels and the E/I ratio, 30/15 ratio and three heart rate variability indi-
ces.11 Furthermore, a recent systematic review and meta-analysis
showed a significant association between vitamin D deficiency and the
development of DPN, particularly in Asian patients.12 In another study,
vitamin D deficiency was related to diabetic painful neuropathy in Greek
but not Bangladeshi patients.13 Shillo et al14 have recently demon-
strated a significantly lower 25(OH)D levels in people with painful com-
pared with painless diabetic neuropathy.
In relation to a mechanistic link between vitamin D and neuro-
pathic pain, nociceptive calcitonin gene-related peptide (CGRP)-posi-
tive neurones have a distinct vitamin D phenotype with hormonally
regulated ligand and receptor levels.15 Vitamin D deficiency results in
increased numbers of axons containing CGRP, and in culture, vitamin
D receptor (VDR) expression is increased in growth cones, and
sprouting appears to be regulated by VDR-mediated rapid response
signalling pathways.16 Nerve growth factor (NGF) is depleted in
experimental diabetes17 and a preservation of NGF expression was
shown in sciatic nerves of diabetic animals treated with a vitamin D
analogue (CB1093). Similarly, tacalcitol, active vitamin D3, induces
NGF production in human epidermal keratinocytes.18 Treatment with
vitamin D3 has been shown to limit demyelination in a cuprizone
experimental model of demyelination19 and in a spinal cord compres-
sion model, it has been shown to induce axonal regeneration.20
In a prospective study of 51 patients with type 2 diabetes and
painful neuropathy treated with 2000 IU of cholecalciferol daily for
3 months, there was a 50% decrease in pain scores as measured by
the Visual Analogue Score (VAS). More recently in a placebo-con-
trolled study of 112 patients with type 2 diabetes randomized to
50 000 IU of cholecalciferol once weekly for 8 weeks, there was a sig-
nificant increase in 25OHD and an improvement in the neuropathy
symptom score, but no change in NDS or neurophysiology.21 In a
study of people with diabetes given 400 IU of vitamin D daily for
12 weeks, there was a significant improvement in pain, numbness and
weakness.22 We have also shown a significant improvement in neuro-
pathic symptoms23,24 and quality of life in patients with painful dia-
betic neuropathy treated with 600 000 IU of vitamin D.
In the present study we have evaluated the levels of 25(OH)D in
patients with painful compared with painless diabetic neuropathy
matched for severity of DPN.
2 | RESEARCH DESIGN AND METHODS
2.1 | Selection of patients
Forty-three patients with type 1 diabetes were categorized into two
groups: painless neuropathy (DPN) (n = 20) and painful neuropathy
(PDN) (n = 23) using the McGill Visual Analogue Score (McGill VAS)
and McGill pain score, and compared with 14 age, sex and ethnicity
matched non-diabetic healthy control subjects (C). Participants with a
history of neurologic conditions, ocular trauma or ocular surgery were
excluded. Participants were randomly selected and not recruited
based on any arbitrary bias such as PDN or vitamin D deficiency
symptoms to ensure selection bias was minimized. The study was
approved by the North West and Salford and Trafford Research Ethics
committee, and written informed consent was obtained according to
the Declaration of Helsinki.
2.2 | Assessment of neuropathy
All patients and control subjects underwent a detailed evaluation with
the neuropathy symptom profile (NSP) and the McGill VAS was used
to assess the severity of painful neuropathy. Neurologic deficits were
assessed using the modified neuropathy disability score, which
includes evaluation of vibration, pinprick and temperature perception
as well as the presence or absence of ankle reflexes. Quantitative sen-
sory testing included an assessment of vibration perception threshold
(VPT), measured using a Neurothesiometer (Horwell, Scientific Labo-
ratory Supplies, Wilford, Nottingham, UK), cold sensation (CST) (Aδ
fibres) and warm sensation (WST) (C fibres) thresholds using the
method of limits with the MEDOC TSA II (Medoc, Ramat Yishai, Israel)
on the dorsum of the left foot.25 Computer-aided sensory evaluator
(CASE IV) (WR Medical Electronic Ltd, Maplewood, Maine, USA) was
used to measure the heart rate response to deep breathing (HRV-DB)
over two eight-cycle breathing series interspersed by a 5-minutes
period of normal breathing. Electro-diagnostic studies were under-
taken using a Dantec ‘Keypoint’ system (Dantec Dynamics, Bristol, U.
K.). Peroneal motor and sural sensory nerves were assessed in the
right lower limb by a consultant neurophysiologist.
2.3 | Corneal confocal microscopy
Patients underwent examination with the Heidelberg retina tomogra-
phy III in vivo corneal confocal microscope employing our established
methodology for image acquisition.26,27 Several scans of the entire
depth of the central cornea were recorded using the section mode,
which enables manual acquisition and storage of single images of all
corneal layers. This provides en face two-dimensional images with a
lateral resolution of 2 mm/pixel and final image size of 400 × 400
pixels of the sub-basal nerve plexus of the cornea. Five images per
patient from the centre of the cornea were selected and examined in
a masked and randomized fashion.28 Three corneal nerve parameters
2 of 8 ALAM ET AL.
were quantified: (a) CNFD, the total number of major nerves per
square millimetre of corneal tissue (no mm2); (b) corneal nerve branch
density (CNBD), the number of branches emanating from all major
nerve trunks per square millimetre of corneal tissue (no mm2) and (c)
corneal nerve fibre length (CNFL), the total length of all nerve fibres
and branches (mm/mm2) within the area of corneal tissue.
2.4 | Skin biopsy and immunohistochemistry
Intra-epidermal nerve fibre density (IENFD) was assessed in a sub-
cohort of participants (Controls n = 10, DPN n = 11, and PDN n = 9)
who agreed to undergo a 3-mm punch skin biopsy from the dorsum
of the foot, 2 cm proximal to the second metatarsal head, after local
anaesthesia (1% lidocaine). The biopsy specimen was immediately
fixed in PBS-buffered 4% paraformaldehyde and after 18 to 24 hours
rinsed in tris-buffered saline and soaked in 33% sucrose (2–4 hours)
for cryoprotection. It was then embedded in optimal cutting tempera-
ture-embedding compound, rapidly frozen in liquid nitrogen, and cut
into 50-μm sections using a cryostat (model OTF; Bright Instruments,
Huntington, UK). Four floating sections per subject were subjected to
melanin bleaching (0.25% KMnO4 for 15 minutes followed by 5%
oxalic acid for 3 minutes), a 4-hour protein block with a tris-buffered
saline solution of 5% normal swine serum, 0.5% powdered milk and
1% Triton X-100, and overnight incubation with 1:1200 Biogenesis
polyclonal rabbit anti-human PGP9.5 antibody (Serotec, Oxford, UK).
Biotinylated swine anti-rabbit secondary antibody (1:300;
DakoCytomation, Ely, UK) was then applied for 1 hour; sections were
quenched with 1% H2O2 in 30% MeOH-PBS (30 minutes) before a 1-
hour incubation with 1:500 horseradish peroxidase–streptavidin (Vec-
tor Laboratories, Peterborough, UK). Nerve fibres were demonstrated
using 3, 3-diaminobenzidine chromogen (Sigma-Aldrich, Manchester,
UK). Sections were mildly counterstained with eosin to better localize
the basement membrane to identify nerve fibres passing through it.
Negative control subjects consisted of replacing the anti-PGP9.5 anti-
body with rabbit immunoglobulin (DakoCytomation) at a concentra-
tion matching that of the primary antibody and showed no
immunostaining. IENFD, that is, the number of fibres per millimetre of
basement membrane, was quantified in accord with established
criteria and techniques and expressed as number per millimetre.29
2.5 | 25(OH) Vitamin D3 Assay
The laboratory used for the biochemical assay measurements (Vitamin D
Research Group Manchester Royal Infirmary, UK) was accredited to ISO
9001:2008 and ISO 13485:2003 by Lloyd's Register Quality Assurance
certificate number LRQ 4001542 and participated successfully in the
Vitamin D quality assurance scheme (DEQAS). Serum was separated from
whole blood and stored at −20C until assay. The assay used was an
automated platform assay (ImmunoDiagnostic Systems Ltd, Bolden, Tyne
and Wear, UK) and is based on chemiluminescence technology. Briefly,
samples were subjected to a pre-treatment step to denature the vitamin
D-binding protein. The treated samples were then neutralized in assay
buffer and a specific anti-25(OH)D antibody labelled with acridinium was
added. Following an incubation step, magnetic particles linked to 25(OH)
D were added. Following a further incubation step, the magnetic particles
were ‘captured’ using a magnet. After a washing step and addition of trig-
ger reagents, the light emitted by the acridinium label was inversely pro-
portional to the concentration of 25(OH)D in the original sample. The
concentration of 25(OH)D was calculated automatically using a 4-point
logistic curve. The cross reactivity for vitamin D2 (of the assay) as per
manufacturers assertion was 100% (relative to vitamin D3) and the assay
has excellent correlation to existing globally recognized assays, in combi-
nation with good sensitivity and precision.30 The reportable range of the
assay was 5–140 ng/mL. Inter- and intra-assay variation of the in-house
control was 5.6% and 9.7%, respectively. Vitamin D deficiency (<20 ng/
mL) and insufficiency (<30 ng/mL) were defined according to the Institute
of Medicine (IOM) of the National Academies.31
2.6 | Statistical analysis
Statistical analyses were undertaken on StatsDirect (StatsDirect, Chesh-
ire, UK). All values are presented as mean ± SD. ANOVA method or a
non-parametric counterpart Kruskal-Wallis was used to assess differ-
ences between groups depending on normality of the data. Overall, the
P value was maintained at .05 for multiple comparison tests (Bonferroni
adjustment or Dwass-Steel-Chritchlow-Fligner pairwise comparison).
Unpaired t test or Mann-Whitney U test were used for analysis for DPN
vs PDN for the duration of diabetes and IENFD. Chi-squared analyses
were used to assess frequencies of gender, ethnicity and aetiology of
diabetes. Odds Ratios for painful symptoms were calculated by further
delineating DPN and PDN groups based on the cut offs for vitamin D
deficiency (<20 ng/mL) and insufficiency (<30 ng/mL).
3 | RESULTS
3.1 | Demographics, metabolic and anthropometric
assessment
The participant demographics and metabolic and anthropometric mea-
surements in people with diabetes and control subjects are summa-
rized in Table 1. There were no significant differences in age, gender,
BMI, duration or type of diabetes and all subjects were of white Euro-
pean origin. HbA1c (P < .0001) was significantly higher in those with
diabetes compared with control subjects with no difference between
patients with PDN and DPN. The total cholesterol was significantly
lower in participants with DPN (P = .003) and PDN (P = .02) compared
with control subjects, due to greater statin use. HDL, triglycerides,
systolic and diastolic blood pressure were comparable between diabe-
tes groups (DPN and PDN) and control subjects. The estimated glo-
merular filtration rate was comparable between diabetes groups and
control participants, but the albumin–creatinine ratio (ACR) was
higher in the DPN (P = .009) and PDN (P = .002) groups compared
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with control subjects with a higher ACR in PDN compared with DPN.
Serum vitamin B12 levels were comparable between groups.
3.2 | Symptoms and deficits
The NSP was significantly higher in PDN compared with DPN
(P < .0005) and control subjects (P < .0001) (Table 2). Positive symp-
toms (out of 6) were significantly greater in PDN compared with DPN
(P = .009) and control subjects (P = .05). Negative symptoms (out of 4)
were significantly greater in PDN compared with DPN (P = .02) and
control subjects (P = .009). The McGill pain score and McGill VAS
were significantly greater in PDN compared with DPN (P < .0001) and
control subjects (P < .0001). The NDS was significantly greater in
patients with DPN (P = .01) and PDN (P = .002) compared with control
subjects, but there were no difference between DPN and PDN.
3.3 | Quantitative sensory tests
VPT, CST and WST did not differ between diabetes groups and con-
trol subjects or between patients with DPN and PDN (Table 3).
TABLE 1 Participant demographics and metabolic parameters in control subjects and patients with DPN and PDN, with statistically
significant differences between groups
C (n = 14) DPN (n = 20) PDN (n = 23) DPN vs PDN
Age (years) 59.3 ± 7.8 57.1 ± 13.5 59.8 ± 11.7 0.41
Gender (male) (%) 57 60 53 0.61
Ethnicity (White European) (%) 100 100 100 >0.99
Aetiology of diabetes (type 1 DM) (%) — 85 91 0.43
Duration of diabetes (years) — 36.0 ± 17.5 35.5 ± 14.9 0.90
HbA1c (%) 5.7 ± 0.2 8.1 ± 1.1* 8.0 ± 1.5** 0.41
HbA1c (mmol/mol) 38.3 ± 2.5 65.2 ± 12.0* 63.7 ± 16.3**
BMI (kg/m2) 31.0 ± 4.2 28.1 ± 4.1 26.6 ± 4.9 0.24
T-CHL (mmol/L) 5.1 ± 1.2 4.2 ± 1.0† 4.4 ± 0.8†† 0.40
HDL-C (mmol/L) 1.7 ± 0.5 1.7 ± 0.4 1.7 ± 0.6 0.73
Triglycerides 1.6 ± 0.7 1.2 ± 0.5 1.3 ± 0.8 0.97
Systolic BP (mmHg) 138 ± 15 141 ± 26 141 ± 23 0.99
Diastolic BP (mmHg) 77 ± 8 71 ± 7 71 ± 11 0.97







eGFR (mL/min/L.73) 85 ± 7 77 ± 16 78 ± 15 0.82
Serum vitamin B12 (ng/L) 247 ± 69 342 ± 121 317 ± 111 0.54
Note: HbA1c *C vs DPN and **C vs PDN—P < .05. T-CHL †C vs DPN and ††C v vs s PDN—P < .05. ACR ¥C vs DPN and ¥¥C vs PDN—P < .05. Significantly
different values are given in bold.
Abbreviations: ACR, Albumin–Creatinine Ratio; BMI, body mass index; BP, blood pressure; C, controls; DPN, diabetic peripheral neuropathy; eGFR, esti-
mated Glomerular Filtration Rate; HbA1c, Glycated Haemoglobin A1c; HDL, high density lipoprotein cholesterol; PDN, painful diabetic neuropathy; T-CHL,
total cholesterol.
TABLE 2 Neuropathic symptoms and deficits in control subjects and diabetic patients with DPN and PDN, with statistically significant
differences between groups
C (n = 14) DPN (n = 20) PDN (n = 23) DPN vs PDN
NDS (−/10) (Median(IQR) 1.4 ± 1.5 1(0-2) 3.9 ± 3.2* 3.5(1.5-5.5)* 4.5 ± 3.2** 4(2-6)** 0.49
NSP (−/38) (Median(IQR) 1 ± 1.5 0(0-1) 2.2 ± 2.6 1(0.5-2.5) 6.3 ± 5.5 ^̂ 5(2-11) ^̂ <0.0005
+ve symptoms on NSP (−/6) (Median(IQR) 0.5 ± 0.9 (0(0-1) 0.25 ± 0.6 (0(0-0) 1.6 ± 1.8€ (1(0-3)€ 0.009
–ve symptoms on NSP (−/4) (Median(IQR) 0 ± 0 (0(0–0) 0.3 ± 0.4 (0.5(0–1) 1.1 ± 1.2¥ (1(0-2)¥ 0.02
McGill VAS (−/10 cm) 0.5 ± 1.4 0 ± 0 5.7 ± 2.3† <0.0001
McGill pain score (Median (IQR) 0.4 ± 0.9 (0(0–0) 0 ± 0 (0(0-0) 6.1 ± 6.5† (3(2–10) <0.0001
Note: NDS*C vs DPN and **C vs PDN—P < .05; NSP Ĉ vs PDN—P < .05; +ve symptomsC vs PDN—P = .05; –ve symptoms¥C vs PDN—P < .05; McGill VAS
& †C vs PDN—P < .05; McGill pain score†C vs PDN—P < 0.05. Significantly different values are given in bold.
Abbreviations: C, controls; DPN, diabetic peripheral neuropathy; McGill VAS, McGill visual analogue score; NDS, neuropathy disability score; PDN, painful
diabetic peripheral neuropathy; type 1 DM, type 1 diabetes mellitus.
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3.4 | Electrophysiology
Peroneal nerve conduction velocity and amplitude were signifi-
cantly lower in DPN (P = .004, P = .003, respectively) and PDN
(P = .0008, P = .001, respectively) compared with control subjects,
but there was no difference between patients with DPN and PDN
(Table 3). Sural nerve conduction velocity and amplitude were sig-
nificantly lower in DPN (P = .02, P = .007, respectively) and PDN
(P = .005, P = .04, respectively) compared with control subjects,
but there was no significant difference between patients with
DPN and PDN.
3.5 | Autonomic function, IENFD and CCM
HRV-DB did not differ between diabetes groups and control subjects
or between patients with DPN and PDN (Table 3). IENFD did not dif-
fer between patients with DPN and control subjects but was signifi-
cantly reduced in PDN compared with control subjects (P = .05) with
no difference between DPN and PDN. CNFD was significantly
reduced in patients with DPN (P = .0008) and PDN (P < .0001) com-
pared with control subjects with no difference between DPN and
PDN. CNBD was significantly reduced only in patients with PDN
(P < .03) compared with control subjects with no difference between
DPN and PDN. CNFL was significantly reduced in patients with DPN
(P = .03) and PDN (P < .0009) compared with control subjects with no
difference between DPN and PDN.
3.6 | 25(OH)D status
The serum 25(OH)D level was significantly lower in PDN
(24.0 ± 14.1 ng/mL) compared with DPN (34.6 ± 15.0 ng/mL, P = .01)
and control subjects (34.1 ± 8.6 ng/mL, P = .03) (Figure 1). The odds
ratio in favour of painful diabetic neuropathy was 9.8 (P = .003 [95%
CI, 2.2-76.4]) for vitamin D deficiency (<20 ng/mL) and 4.4, (P = .03
(95% CI, 1.1-19.8]) for vitamin D insufficiency (<30 ng/mL).
TABLE 3 Small and large fibre tests of nerve structure and function in control subjects and diabetic patients with DPN and PDN, with
statistically significant differences between groups
C (n = 14) DPN (n = 20) PDN (n = 23) DPN vs PDN
CNFD (no/mm2) 34.6 ± 5.4 24.5 ± 8.4* 20.4 ± 10.0** 0.35
CNBD (no/mm2) 75.9 ± 24.2 56.1 ± 31.8 45.5 ± 29.3† 0.36
CNFL (mm/mm2) 24.3 ± 3.6 19.8 ± 5.7¥ 15.8 ± 7.2¥¥ 0.13
IENFD (no/mm) 7.6 ± 3.4 (n = 10) 5.2 ± 3.7 (n = 11) 3.9 ± 2.9a (n = 9) 0.67
DB-HRV (beats/min) 23 ± 10 18 ± 9 18 ± 14 0.55
CST (C) 27.2 ± 1.9 24.0 ± 6.6 23.5 ± 6.8 0.68
WST(C) 39.8 ± 3.8 40.7 ± 4.7 42.0 ± 4.9 0.35
VPT (volts) 10.7 ± 6.6 17.0 ± 14.0 19.5 ± 13.1 0.35
Sural SNCV (m/s) 47.7 ± 5.1 41.9 ± 6.2 42.2 ± 4.6 0.61
Sural amplitude (μV) 9.6 ± 2.7 6.9 ± 4.8€ 5.3 ± 5.3€€ 0.46
Peroneal MNCV (m/s) 45.9 ± 3.3 38.3 ± 9.3a 38.4 ± 8.7aa 0.64
Peroneal amplitude (mV) 4.9 ± 1.0 2.6 ± 1.9§ 2.6 ± 2.5§§ 0.78
Note: CNFD*C vs DPN and **C vs PDN—P < .05; CNBD†C vs PDN—P < .05; CNFL¥C vs DPN and ¥¥C vs PDN—P < .05; IENFD aC vs PDN—P = .05; Sural
SNCVC vs DPN and C vs PDN—P < .05; Sural SNAmp€C vs DPN and €€C vs PDN—P < .05; Peroneal MNCVaC vs DPN and aaC vs PDN—P < .05; Pero-
neal MNAmp§C vs DPN and §§C vs PDN—P < .05.
Abbreviations: C, controls; CNBD, corneal nerve branch density; CNFD, corneal nerve fibre density; CNFL, corneal nerve fibre length; CST, cold sensation
threshold; DB-HRV, deep breathing—heart rate variability; DPN, diabetic peripheral neuropathy; IENFD, intra epidermal nerve fibre density; PDN, painful
diabetic neuropathy; Peroneal MNAmp, peroneal motor nerve amplitude; Peroneal MNCV, peroneal motor nerve conduction velocity; Sural SNAmp, sural
nerve sensory nerve amplitude; VPT, vibration perception threshold; WST, warm sensation threshold.
F IGURE 1 Graph showing 25(OH)D levels in ng/mL in controls
and patients with DPN and PDN. C vs DPN—P = NS, *C vs PDN—
P = .03, **DPN vs PDN—P = .01 (Overall P for Kruskal Wallis = .02)
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4 | DISCUSSION
Painful diabetic neuropathy is an extremely disabling condition, which
may be present in at least one-fifth of people with diabetes.4 The
treatment of this condition is unsatisfactory with a ‘good’ response to
conventional medication rated at between 30% to 50% pain relief.32
Available drugs are often moderately effective and their use is limited
by side effects. Furthermore, recent studies of novel drugs in the
treatment of painful diabetic neuropathy have failed to show effi-
cacy.33,34 There is an urgent need to explore new mechanisms and
treatments for diabetic painful neuropathy.
The aetiology of painful diabetic neuropathy is not clear. Central
changes comprising of increased thalamic vascularity,35 Aβ fibre
sprouting into lamina II of the dorsal horn and reduced inhibition via
descending inhibitory pathways5 together with axonal atrophy in
peripheral nerves have been demonstrated in patients with painful
diabetic neuropathy.36 Painful diabetic neuropathy has also been
associated with autonomic dysfunction.37 Previously, we have shown
that the LDI flare, a measure of small fibre function, is abnormal in
patients with painful diabetic neuropathy, whereas conventional
quantitative sensory testing and dermal nerve fibre density did not
differ from those with painless diabetic neuropathy.38
In the present study, we carefully phenotyped diabetic patients
into those with painful and painless diabetic neuropathy and under-
took detailed assessment of large and small fibre neuropathy. There
was no difference for electrophysiology, quantitative sensory testing
and autonomic function between painful and painless neuropathy.
Previously, we have shown a greater reduction in both intraepidermal
nerve and corneal nerve fibre length in painful diabetic neuropathy39
and a detailed immunophenotyping study has shown increased axonal
growth (higher GAP43/PGP) and axonal swellings, positive for tropo-
myosin-receptor-kinase A and substance P in patients with painful
compared with painless neuropathy.40 In the present study, there was
no significant difference in autonomic function, IENFD or corneal
nerve morphology between painful and painless neuropathy. Indeed,
we have recently shown that corneal nerve length at the inferior
whorl as opposed to more central corneal nerve parameters differ
between patients with and without painful diabetic neuropathy.41
Given that painful neuropathic symptoms vary in their severity
over time, particularly with nocturnal exacerbation, it is difficult to
reconcile these ‘hard wired’ changes with the fluctuating symptoms.
Therefore, changes in sodium channel distribution and expression,
altered peripheral blood flow and glycaemic flux have also been impli-
cated in painful diabetic neuropathy.5 Given the potential link
between vitamin D and pain, together with the high prevalence of
vitamin D deficiency in diabetic populations,42 we have explored the
link with painful diabetic neuropathy. Previous studies have shown a
relationship between vitamin D deficiency and diabetic neuropathy,7,8
but did not specifically assess the relationship to painful diabetic neu-
ropathy. In the present study, we show a markedly increased risk of
painful diabetic neuropathy particularly in patients with vitamin D
deficiency but also in those with insufficiency. These data are in keep-
ing with those of a recently published study.14 A large epidemiological
study has shown a higher prevalence of painful diabetic neuropathy in
South Asians compared with Europeans.4 In our previous study, we
showed that 55% of South Asians were severely vitamin D deficient
with a 25(OH)D < 10 ng/mL.42 The cohort of subjects evaluated in
this study was exclusively white European thus minimising ethnicity
as a confounding factor. However, a large population-based study
(n = 1461) from China indicated a low vitamin D concentration to be a
risk factor for diabetic neuropathy in older adults (≥65 years)
(P < .05).43 There was no such relationship in the youth or middle-
aged groups suggesting an age-related differential effect.43
Although vitamin D has been used to treat pain in rheumatologi-
cal conditions,44 a Cochrane review concluded that there was poor
evidence for the efficacy of vitamin D in the treatment of chronic
pain.45 Valensi et al46 showed an improvement in painful neuropathic
symptoms with a topical compound (QR-333) containing quercetin,
ascorbyl palmitate and vitamin D3. Lee et al47 showed that oral chole-
calciferol significantly improved symptoms of painful diabetic neurop-
athy, however, this study lacked randomization and a placebo group.
Treatment with vitamin D produced a dramatic improvement in the
symptoms of painful diabetic neuropathy in a type 1 patient, refrac-
tory to a range of standard therapies.48 We have also shown that
treatment with high-dose vitamin D results in a significant reduction
in neuropathic symptoms23 and improves the quality of life24 in
patients with painful diabetic neuropathy. More recently, a study
using low-level laser therapy in people with painful diabetic neuropa-
thy raised 25(OH)D levels and there were improvements in neuro-
pathic pain and quality of life.49
Limitations of the current study are the small sample size, lack
of quantification of sunlight exposure or daily activity and compari-
son with a non-neuropathic diabetic cohort. However, a major
strength is the detailed phenotyping undertaken to ensure that dia-
betic patients with and without painful neuropathy were absolutely
matched for all clinical and metabolic variables as well as the severity
of neuropathy.
We demonstrate a relationship between vitamin D deficiency and
painful diabetic neuropathy. A well-constructed clinical trial of vitamin
D in painful diabetic neuropathy is required to assess the effective-
ness of a potentially simple treatment with no obvious side effects.
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